Amgen Inc.
ANTI-IL13 ANTIGEN BINDING PROTEINS

Last updated:

Abstract:

The present invention is related to antibodies directed to IL-13 and uses of such antibodies. For example, in accordance with the present invention, there are provided human monoclonal antibodies directed to IL-13. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), are provided. Additionally, methods of using these antibodies to treat patients are also provided.

Status:
Application
Type:

Utility

Filling date:

24 Jul 2020

Issue date:

8 Sep 2022